Tocilizumab (International)

In the US, Tocilizumab (tocilizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat COVID-19, Cytokine Release Syndrome, Giant Cell Arteritis, Juvenile Idiopathic Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Still's Disease, Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease.

US matches:

• Tocilizumab
• Tocilizumab-bavi
• Tocilizumab (Intravenous)
• Tocilizumab Prefilled Syringes

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AC07

CAS registry number (Chemical Abstracts Service)

0375823-41-9

Chemical Formula

C6428-H9976-N1720-O2018-S42

Molecular Weight

144985

Therapeutic Categories

Immunosuppressant

Monoclonal antibody

Chemical Name

immunoglobulin G1, anti-(human interleukin 6 receptor) (human-mouse monoclonal MRA heavy chain), disulfide wit human-mouse monoclonal MRA kappa-chain, dimer (WHO)

Foreign Names

• Tocilizumabum (Latin)
• Tocilizumab (German)
• Tocilizumab (French)
• Tocilizumab (Spanish)

Generic Names

• Tocilizumab (OS: USAN)
• Tocilizumab (Genetical Recombination) (OS: JAN)
• Atlizumab (IS)
• MRA (IS)
• R-1569 (IS)

Brand Names

• Actembra
  Roche, Egypt
• Actemra
  Chugai, Georgia; Chugai Pharma, Oman; Chugai Pharmaceutical, Japan; F. Hoffmann-La Roche, Macedonia; Galenika AD, Serbia; Genentech, United States; Hoffmann-La Roche, Canada; Productos Roche, Chile; Roche, Armenia; Roche, Netherlands Antilles; Roche, Argentina; Roche, Aruba; Roche, Azerbaijan; Roche, Bosnia & Herzegowina; Roche, Belarus; Roche, Ecuador; Roche, Hong Kong; Roche, India; Roche, Kyrgyzstan; Roche, Moldova; Roche, Myanmar; Roche, Malaysia; Roche, New Zealand; Roche, Oman; Roche, Peru; Roche, Philippines; Roche, Paraguay; Roche, Russian Federation; Roche, Thailand; Roche, Turkmenistan; Roche, Tunisia; Roche, Uruguay; Roche, Vietnam; Roche, South Africa; Roche D.O.O., Serbia; Roche Products, Australia; Vetter, Georgia; Vetter, Russian Federation; Roche Pharma Schweiz, Switzerland
• ACTEMRA
  Roche Pharmaceutical, China
• Actemra 162mg
  Roche, Israel
• Actemra 200mg/10ml
  Roche, Turkey
• Actemra 20mg/ml
  Roche, Israel
• Actemra 400mg/20ml
  Roche, Turkey
• Actemra 80mg/4ml
  Roche, Turkey
• Acterma
  Chugai Pharma, Kenya; Roche, Brazil
• Acterma SC
  Roche, Brazil
• Aktempa
  Roche, Ukraine
• Roaccutane
  Roche, Cyprus
• RoActemra
  Hoffmann-La Roche Ltd, Latvia; Roche, Belgium; Roche, Czech Republic; Roche, Denmark; Roche, Estonia; Roche, Spain; Roche, Finland; Roche, France; Roche, Greece; Roche, Croatia (Hrvatska); Roche, Ireland; Roche, Lithuania; Roche, Mexico; Roche, Norway; Roche, Poland; Roche, Sweden; Roche - Germania, Romania; Roche Products, United Kingdom; Roche Registration, Netherlands; Roche Registration Limited, Iceland; Roche Registration, Slovenia
• RoActemra 162 mg
  Roche, Hungary
• RoActemra 162mg
  Chugai Pharma, Germany; Roche, Germany; Roche, Luxembourg; Roche Registration, Austria
• RoActemra 20 mg/ml
  Roche, Hungary
• RoActemra 20mg/ml
  Chugai Pharma, Germany; Roche, Germany; Roche, Luxembourg; Roche Registration, Austria

Glossary

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer